On March 14, 2023 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, reported that four abstracts, including a late-breaking abstract, highlighting preclinical data from both the hypoimmune and fusogen platforms have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 14-19, 2023 in Orlando, FL (Press release, Sana Biotechnology, MAR 14, 2023, View Source [SID1234628660]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Late-breaking poster details:

Title: Increased potency of CD8-targeted fusosomes enhances CAR gene delivery to resting primary T cells
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date: Wednesday, April 19, 2023
Session Time: 9:00 a.m. – 12:30 p.m. ET
Location: Poster Section 35
Abstract Number: LB311

Poster details:

Title: Modulation of resting T cell status to enhance transduction and CAR T expansion following exposure to CD8-targeted fusosomes
Session Category: Experimental and Molecular Therapeutics
Session Title: Gene and Vector-based Therapy
Session Date: Monday, April 17, 2023
Session Time: 1:30 p.m. – 5:00 p.m. ET
Location: Poster Section 16
Abstract Number: 2734

Title: Development of a novel, fully human anti-CD19 chimeric antigen receptor for in vivo delivery via CD8-targeted fusosome
Session Category: Experimental and Molecular Therapeutics
Session Title: Gene and Vector-based Therapy
Session Date: Monday, April 17, 2023
Session Time: 1:30 p.m. – 5:00 p.m. ET
Location: Poster Section 16
Abstract Number: 2735

Title: Engineered hypoimmune CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with re-challenge
Session Category: Immunology
Session Title: CAR T-cell Therapy 2
Session Date: Tuesday, April 18, 2023
Session Time: 9:00 a.m. – 12:30 p.m. ET
Location: Poster Section 23
Abstract Number: 4091

Full regular abstracts and late-breaking abstract titles are available for viewing via the AACR (Free AACR Whitepaper) Online Itinerary Planner located here: View Source!/10828. Late-breaking abstract text will be posted to the AACR (Free AACR Whitepaper) Online Itinerary Planner and Meeting App on Friday, April 14, 2023 at 12:00 p.m. ET.

On March 14, 2023 RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, reported financial results for the fourth quarter and year ended December 31, 2022 (Press release, RAPT Therapeutics, MAR 14, 2023, https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-reports-fourth-quarter-and-year-end-financial [SID1234628659]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"2022 was an important year of progress, as we advanced both of our two lead programs, RPT193 and FLX475, in inflammatory disease and cancer, respectively," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. "This progress has positioned us for future milestones in 2023, including our anticipated initiation of a Phase 2a trial with RPT193 in asthma this quarter and a clinical data update from our ongoing Phase 2 trial of FLX475 in multiple cancer indications, which we are targeting for the second half of this year. For our Phase 2b trial of RPT193 in atopic dermatitis, we now expect topline results in mid-2024 due to recent slower than expected patient enrollment as we did not see the seasonal uptick that we anticipated. Our cash position is strong and we expect it to provide runway into mid-2025, well beyond the expected data readout."

Financial Results for the Fourth Quarter and Year Ended December 31, 2022

Fourth Quarter Ended December 31, 2022

Net loss for the fourth quarter of 2022 was $23.0 million, compared to $17.9 million for the fourth quarter of 2021.

Research and development expenses for the fourth quarter of 2022 were $19.5 million, compared to $14.3 million for the same period in 2021. The increase in research and development expenses was primarily due to higher development costs related to RPT193 and FLX475, personnel and stock-based compensation expense.

General and administrative expenses for the fourth quarter of 2022 were $5.0 million, compared to $4.5 million for the same period in 2021. The increase in general and administrative expenses was primarily due to increases in expenses for personnel, stock-based compensation and facilities, partially offset by a decrease in professional services.

Year Ended December 31, 2022

Net loss for the year ended December 31, 2022 was $83.8 million, compared to $69.2 million in 2021.

Research and development expenses for the year ended December 31, 2022 were $67.1 million, compared to $57.0 million in 2021. The increase in research and development expenses was primarily due to higher development costs related to RPT193 and increases in expenses for early-stage programs, personnel and laboratory supplies, partially offset by decreases in development costs related to FLX475, facilities costs and stock-based compensation expense.

General and administrative expenses for the year ended December 31, 2022 were $20.2 million, compared to $16.0 million in 2021. The increase in general and administrative expenses was primarily due to increases in expenses for professional services, personnel, stock-based compensation and facilities.

As of December 31, 2022, the Company had cash, cash equivalents and marketable securities of $249.1 million. In December 2022, we completed an underwritten public offering of 4,338,104 shares of common stock and received approximately $75.0 million in net proceeds, after deducting underwriting discounts and other offering-related costs.

On March 14, 2023 Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, reported the upcoming presentation of new clinical data from its Phase 1 study of PRTX007, an orally administered prodrug of a novel, small molecule toll-like receptor 7 (TLR7)-specific agonist, at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Primmune Therapeutics, MAR 14, 2023, View Source [SID1234628658]). The AACR (Free AACR Whitepaper) Annual Meeting will be held in Orlando, Florida from April 14-19. An e-poster will be made available online Friday, April 14 at 12 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Title: Activation of innate and adaptive immune response with a clinical stage TLR7 agonist prodrug PRTX007
Presenting Author: Curtis Scribner, M.D.
Abstract Number: CT180
Session Title: First-in-Human Phase I Clinical Trials 2
Session Date and Time: Tuesday, April 12, 9 a.m. CT to 12:30 p.m. CT
Location: Orange County Convention Center, Poster Section 45

About PRTX007
PRTX007, Primmune’s lead clinical development candidate, is designed to provide well-tolerated, controlled, long-term stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses. PRTX007 administration uniquely activates plasmacytoid dendritic cells (pDCs), leading to a systemic immune poly-IFN response without stimulating production of NF-κB-driven proinflammatory factors like IL-6, TNFα or IL-1β. Activated pDCs directly deliver interferons to target cells by paracrine transfer. Conceptually, this is equivalent to administering a therapeutically effective cocktail of all Type I/III IFNs while avoiding the associated side effects and adverse events. Furthermore, PRTX007 administration leads to systemic activation of anti-tumor effector CD8+ T cells and NK cells. PRTX007 is being rapidly advanced towards clinical trials for solid tumors in the advanced cancer setting and for clearing human papillomavirus-transformed pre-cancerous cervical lesions.

On March 14, 2023 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported that two abstracts have been accepted for poster presentations at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 14-19, 2023, in Orlando, FL (Press release, ORIC Pharmaceuticals, MAR 14, 2023, View Source [SID1234628656]). The presentations will highlight:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

preclinical biomarker results for ORIC-944, a potent and selective allosteric inhibitor of PRC2 currently in Phase 1 for patients with metastatic prostate cancer; and
preclinical data from ORIC’s selective PLK4 inhibitor discovery program
Details of the presentations are as follows:

Title: Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic
Session Category: Experimental and Molecular Therapeutics
Session Title: Pharmacokinetics, Pharmacodynamics, and Molecular
Pharmacology
Session Date & Time: Monday, April 17, 2023, 1:30 p.m. – 5:00 p.m. ET
Location: Poster Section 18
Abstract Number: 2791

On March 14, 2023 Onxeo S.A. (Euronext Growth Paris: ALONX), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, reported new dates for the publication of its 2022 full-year results and the holding of its annual general meeting (Press release, Onxeo, MAR 14, 2023, View Source [SID1234628655]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company’s Board of Directors decided to schedule the publication of the 2022 full-year results on April 14, 2023, after market close, and the holding of its annual general meeting on June 6, 2023. The date for the publication of the 2023 half-year results, scheduled for September 28 after market close, remains unchanged.